Spis treści:
Spis załączników:
SFA_Sales_Revenues_May_2024_espi.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
SFA_Sales_Revenues_May_2024_espi.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 56 | / | 2024 | ||||||||
| Date of issue: | 2024-06-20 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Sales revenues for May 2024 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, June 20, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Sequrities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for May 2024 the Company recorded a decrease in sales of 20% compared to the same month of the previous year, incl. 14% decrease in domestic sales and 23% decrease in export sales. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_Sales_Revenues_May_2024_espi.pdfSFA_Sales_Revenues_May_2024_espi.pdf | Sales revenues for May 2024 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2024-06-20 | Ognian Donev | Executive director | |||
Źródło:Komunikaty spółek (ESPI)
